GFAP and Alzheimer disease: Under these circumstances, the diagnostic and prognostic performance of GFAP in CSF and serum/plasma for AD should be further evaluated and verified with better analytical assays in larger-scale cohorts, especially for different age groups and clinical contexts (Hansson et al., 2022).